

Supplementary Table 1. Baseline characteristics of the primary Sjögren syndrome study population. Values are presented as number (%) of patients, mean \pm SD, or median (interquartile range).

Characteristics	Rituximab, N = 18	Abatacept, N = 13
Age (years)	40 (32-57)	41 (32-50)
Female gender (%)	17 (94)	11 (85)
Disease duration (months)	59 (37-90)	11 (7-37)
IgG (g/l)	21 (17-27)	20 (18-28)
RF (kIU/L)	107 (32-223)	62 (22-190)
Anti-Ro / SSA positive (%)	18 (100)	13 (100)
Anti-La / SSB positive (%)	13 (72)	10 (77)
ACPA positive (%)	0 (0)	0 (0)
UWS (ml/min)	0.09 (0.03-0.30)	0.13 (0.06-0.23)
SWS (ml/min)	0.30 (0.15-0.54)	0.39 (0.20-0.62)
Schirmer's I test (mm/5 min)	7 (1.5-11)	8 (4-16.5)
Tear break-up time (sec)	5 (3-7)	8 (4-10)
DAS28-ESR	3.7 (3.4-5.0)	4.5 (3.9-5.9)
SJC	2 (0-3)	2 (0-8)
TJC	4 (0-7)	8 (2-13)
ESR	34 \pm 14	31 \pm 18
VAS	69 \pm 17	60 \pm 16
DAS28-CRP [#]	4.3 (3.5-5.2)	4.9 (4.0-5.4)
ESSDAI	8.5 (5-11.5)	11 (8-15)
Cutaneous domain (%)	2 (11)	4 (31)
Respiratory domain (%)	3 (17)	2 (15)
Renal domain (%)	0 (0)	0 (0)
Articular domain (%)	7 (39)	12 (92)
Muscular domain (%)	0 (0)	0 (0)
PNS domain (%)	2 (11)	1 (8)
CNS domain (%)	0 (0)	0 (0)
Hematological domain (%)	8 (44)	2 (15)
Glandular domain (%)	11 (61)	9 (69)
Constitutional domain (%)	8 (44)	5 (38)

Lymphadenopathy domain (%)	0 (0)	1 (8)
Biological domain (%)	17 (94)	11 (85)
ESSPRI	7.3 (6.3-8.3)	7.3 (6-7.9.0)
Parotid biopsy characteristics		
Focus score ≥ 1	17 (94)	13 (100)
Lymphoepithelial lesions	8 (44)	9 (69)
Shift IgA to IgG	15 (83)	12 (92)
Germinal centers	5 (28)	0 (0)

‡ Selected patients from rituximab (N=11) or abatacept (N=11) groups with DAS28-CRP ≥ 3.2 . RF, rheumatoid factor; ACPA, anticitrullinated protein antibodies; UWS, unstimulated whole salivary flow rate; SWS, stimulated whole salivary flow rate; DAS2-8ESR, Disease Activity Score in 28 joints, including erythrocyte sedimentation rate (ESR); DAS2-8CRP, Disease Activity Score in 28 joints, including C-reactive protein; SJC, swollen joint count; TJC, tender joint count; VAS, visual analog scale; ESSDAI, EULAR Sjögren's Syndrome Disease Activity Index; ESSPRI, EULAR Sjögren's Syndrome Patient Reported Index; EULAR, European League Against Rheumatism; PNS, peripheral nervous system; CNS, central nervous system.